Merck 与 Moderna 的个体化 mRNA 癌症疫苗 intismeran 首个关键试验显示复发或死亡风险降低 42%
STAT+: After a cancer vaccine’s first success, the race is on to expand the impact
在 ESMO 会议上公布的 Merck 与 Moderna 个体化 mRNA 疫苗 intismeran 关键试验显示，联合 Keytruda 相比单用 Keytruda 使复发或死亡风险降低 42%。
同一件事，精选收录的是《Merck 与 Moderna 的 mRNA 癌症疫苗降低黑色素瘤复发风险，机制仍不清楚》
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
MADRID — With the first pivotal trial showing a customized mRNA treatment improved outcomes for cancer patients presented here this weekend, the conversation has already turned to how melanoma specialists should adopt the medicine — and how widely these novel vaccines can be deployed.
“In principle, this type of approach may be applicable to other types of tumors,” James Larkin of London’s Royal Marsden Hospital, the scientific co-chair for this year’s European Society for Medical Oncology meeting, said at an opening press conference.
The trial, from Merck and Moderna, demonstrated that the bespoke mRNA-based vaccine intismeran reduced the risk of recurrence or death by 42% when combined with Merck’s checkpoint inhibitor Keytruda versus Keytruda alone. The results are a clear victory for the field after what Vinod Balachandran of Memorial Sloan Kettering Cancer Center called in a lecture a “long and sordid” history of trying to develop cancer vaccines that, until now, has essentially added up to 100 years of failure.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源：STAT News · statnews.com